PR Newswire BiotechOriginal article
Lunai Bioworks (Nasdaq: LNAI) Signs Definitive Collaboration Agreement with BrainStorm Therapeutics; Initial Parkinson's Disease Data Readout Targeted for First Half of 2027
PartnershipPositive
AI Analysis
Summary
Lunai Bioworks signed a definitive collaboration agreement with BrainStorm Therapeutics to develop an integrated roadmap for Parkinson's Disease treatment using AI-driven patient stratification and biomarker development, with initial data readout targeted for the first half of 2027.
Clinical Trial Data
Outcome Details
Definitive collaboration agreement and master collaboration agreement established with integrated roadmap for AI-driven patient stratification, human translational validation, biomarker development, and pharmaceutical partnering
Importance:6/10
Sentiment:
0.50
Parkinson's DiseaseAI-driven stratificationbiomarker developmentcollaboration agreementdata readout
Related Companies
Read the original article
Published by PR Newswire Biotech on August 4, 2026 7:28 PM